Harald Weinstabl

Harald is currently a director of Medicinal Chemistry I&R (Immunology & Respiratory) at Boehringer Ingelheim. Prior to this role, he was department head Medicinal Chemistry CRCI, at Boehringer Ingelheim RCV (Vienna). Harald contributed to multiple milestone transitions in the portfolio, led the establishment of the PROTAC platform at Boehringer and delivered the structural core of Brigimadlin, a clinical PhIII mdm2i. He is active member of the AACR – CRCI working group and contributed to multiple donated probes on opnMe. Harald received his PhD under supervision of Johann Mulzer in total synthesis of complex natural products. After a Postdoc in Toronto (with Mark Lautens), he joined Boehringer Ingelheim RCV in Vienna in 2013 as a principal scientist in Medicinal Chemistry in Oncology research.